Q-omics provides the consensus-scored UQCRB profile across patient tissues and cancer cell-line models. UQCRB expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, UQCRB is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, UQCRB protein abundance shows 22,662 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, BLCA, and GBM as cancer lineages where UQCRB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UQCRB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UQCRB survival associations across molecular data types. UQCRB RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UQCRB RNA expression–survival associations across cancer types. High UQCRB expression shows unfavorable associations in SCLC, UVM, UCS, LUAD and HNSC, but favorable associations in LGG. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for UQCRB RNA expression.
This table summarizes UQCRB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UQCRB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UQCRB shows lower tumor expression in BLCA, KIRC and READ and higher tumor expression in LIHC, CHOL and KICH. The BLCA box plot shows higher UQCRB RNA expression in normal versus tumor tissue (log2 FC = −0.784, t-test p < 0.001).
This table shows molecular features associated with UQCRB in patient tissues and cancer cell lines. In patient samples, UQCRB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, UQCRB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
